Bladder Cancer, Genitourinary Cancer, Immunotherapy CE/CME ACCREDITED Watch Time: 59 mins

touchCONGRESS Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022

Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress.

Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now

Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
CE/CME ACCREDITED Next Chapter
Introduction
Latest efficacy and safety data for immunotherapies and targeted treatments for bladder cancer
Future directions in the use of immunotherapy and targeted therapies for the treatment of bladder cancer
Recent data on biomarkers and prognostic factors for immunotherapy and targeted treatment outcomes in patients with bladder cancer
Video Player Controls:
 
Take CE/CME Test
Overview

Watch Prof. Axel Merseburger summarize and share his interpretation of the latest data from the ESMO Congress 2022 on immunotherapies and targeted treatments for bladder cancer. During the presentation he considers:

  • Latest efficacy and safety data for immunotherapies and targeted treatments for bladder cancer
  • Future directions in the use of immunotherapy and targeted therapies for the treatment of bladder cancer
  • Recent data on biomarkers and prognostic factors for immunotherapy and targeted treatment outcomes in patients with bladder cancer
Downloads

View and download resources from this activity to support your learning or share with colleagues

Download Slides

Axel Merseburger is professor of urology and chairman of the Department of Urology at University Hospital Schleswig-Holstein, Campus Lübeck, Germany. read more

Prof. Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, with specific interest in biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma.

Prof. Merseburger is a member of various uro-oncology organisations, he is the chairman elect for the European Scholarship Program (ESUP) of the European Association of Urology (EAU) and was the chairman of the EAU Guideline Group for Lasers and Technologies. He acts as reviewer and editorial board member for several urology and oncology indexed journals, and is associate editor of the World Journal of Urology and editor-in-chief of the European Journal of Haematology and Oncology and Aktuelle Urologie.

He has authored and co-authored more than 300 peer-reviewed articles, and he is the principal investigator in multiple phase II and III clinical trials within the field of urologic oncology.

Prof. Axel Merseburger discloses Advisory board or panel fees from Astellas, Bayer, Ipsen, Janssen and Roche. Consultancy fees from Astellas, Bayer, Ipsen, Janssen and Roche. Speaker’s bureau fees from Astellas, Bayer, Ipsen, Janssen and Roche.

  • Part 2: Expert interviews
Dr Bradley McGregor
Watch Time: 10:08 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Dr McGregor considers the latest data from ESMO Congress 2022 on existing and emerging treatments for bladder cancer, their role in the improvement of patient outcomes and their impact on daily practice.
 
Take CE/CME Test
Prof. Axel Merseburger
Watch Time: 05:12 University Hospital Schleswig-Holstein Campus Lübeck, Germany

Prof. Axel Merseburger considers the latest data from ESMO Congress 2022 on existing and emerging treatments for bladder cancer, their role in the improvement of patient outcomes and their impact on daily practice.
 
 
Take CE/CME Test
Prof. Andrea Necchi
Watch Time: 13:04 Vita-Salute San Raffaele University, Milan, Italy

Prof. Andrea Necchi considers the latest data from ESMO Congress 2022 on existing and emerging treatments for bladder cancer, their role in the improvement of patient outcomes and their impact on daily practice.
 
 
Take CE/CME Test
Please Select A Video:
Dr Bradley McGregor
 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Watch Time: 10:08 Translations available:
Watch Video
Prof. Axel Merseburger
 University Hospital Schleswig-Holstein Campus Lübeck, Germany Watch Time: 05:12 Translations available:
Watch Video
Prof. Andrea Necchi
 Vita-Salute San Raffaele University, Milan, Italy Watch Time: 13:04 Translations available:
Watch Video
Take CE/CME Test
Overview & Learning Objectives
Overview

Stay up to date with the latest data on existing and emerging treatments for bladder cancer and how clinical practice is changing to improve patient outcomes in this two-part activity. This activity was filmed during the ESMO Congress 2022 (Paris, 9–12 September 2022).

This activity is jointly provided by USF Health and touchIME. read more

Target Audience

This activity has been designed to meet the educational needs of oncologists, including genitourinary cancer sub-subspecialists and urologists involved in the management of patients with bladder cancer.

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty 

Dr Bradley McGregor discloses: Advisory board or panel fees from Astellas, Bristol Myers Squibb (BMS), Calithera Biosciences, Dendreon, Eisai, EMD Serono, Exelixis, Merck KGaA, Pfizer and Seattle Genetics. Consultancy fees from Janssen Oncology. Grants/research support from Astellas, Bristol Myers Squibb (BMS), Calithera Biosciences, EMD Serono, Exelixis, Pfizer and Seattle Genetics.

Prof. Axel Merseburger discloses: Advisory board or panel fees from Astellas, Bayer, Ipsen, Janssen and Roche. Consultancy fees from Astellas, Bayer, Ipsen, Janssen and Roche. Speaker’s bureau fees from Astellas, Bayer, Ipsen, Janssen and Roche.

Prof. Andrea Necchi discloses: Advisory board or panel fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Catalym, Gilead, Incyte, Janssen, Merck, Pfizer and Roche. Consultancy fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Catalym, Gilead, Incyte, Janssen, Merck, Pfizer and Roche. Grants research support from AstraZeneca, Gilead and Merck.

Content reviewer

Lucas Wiegand, MD has no relevant financial relationships to disclose.

Touch Medical Director

Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu.

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 3 October 2022. Date credits expire: 3 October 2023.

If you have any questions regarding credit please contact cpdsupport@usf.edu.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the latest efficacy data for new and emerging targeted treatments for patients with bladder cancer
  • Describe the safety profile of new and emerging targeted treatments for patients with bladder cancer
  • Discuss how the latest data on targeted treatments may affect the current and future management of patients with bladder cancer
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from Seagen Inc. and Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.

The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits /contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals.

Date of original release: 3 October 2022. Date credits expire: 3 October 2023.

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
CE/CME Test (1.0 Points) Close
CE/CME Test

To obtain the CME credit(s), please complete this post-test. Please complete and click to see your results and continue.
Question 1/5
When treating your patients with high-risk muscle invasive urothelial carcinoma with neoadjuvant pembrolizumab as part of a clinical trial, which of the following patient subgroups would you expect to have the highest rate of event-free survival?

FGFR1, fibroblast growth factor receptor 1; PD-L1, programmed death-ligand 1.
 Correct

The phase II, open-label PURE-01 trial of pembrolizumab before radical cystectomy reported that patients with PD-L1 expression ≥10% had a 3-year event-free survival rate of 83% compared with 63% in patients with PD-L1 expression <10%.

Abbreviation

PD-L1, programmed death-ligand 1.

Reference

Padua TC, et al. Presented at: ESMO 2022, Paris, France. 9–12 September 2022. Abstr 1738P.

Question 2/5
Based on real-world data presented at ESMO 2022, what is the overall response rate to treatment with enfortumab-vedotin in patients with advanced or metastatic urothelial carcinoma whose disease progressed after first-line chemotherapy?

ESMO, European Society for Medical Oncology.
 Correct

A retrospective, multicentre real-world study from 11 tertiary treatment centres reported that patients with advanced or metastatic urothelial carcinoma who had received second-line enfortumab-vedotin after first-line chemotherapy had an overall response rate of 28.6%.

Reference

Darr C, et al. Presented at: ESMO 2022, Paris, France. 9–12 September 2022. Abstr 1759P.

Question 3/5
What did real-world data from the AVENANCE study, presented at ESMO 2022, tell us about the safety profile of avelumab for maintenance therapy after first-line platinum-based chemotherapy in patients with locally advanced or metastatic urothelial carcinoma?

ESMO, European Society for Medical Oncology.
 Correct

The AVENANCE study reported that 28.1% of patients experienced serious treatment-related adverse events.

Reference

Barthelemy P, et al. Presented at: ESMO 2022, Paris, France. 9–12 September 2022. Abstr 1757P.

Question 4/5
Your patient is a 64-year-old man with stage IV metastatic urothelial carcinoma ineligible for treatment with cisplatin. He is enrolled in a clinical trial of first-line enfortumab–vedotin. During this trial which adverse event would you actively monitor for?
 Correct

A phase I/II, randomized, open-label trial of first-line enfortumab–vedotin as a monotherapy or in combination with pembrolizumab in cisplatin-ineligible patients reported that 43.8% of patients receiving enfortumab–vedotin alone experience peripheral neuropathy.

Reference

Rosenberg JE, et al. Presented at: ESMO 2022, Paris, France. 9–12 September 2022. Abstr LBA73.

Question 5/5
Assuming you had access to relevant biomarker testing, which of the following would you consider a potential biomarker of disease-free survival in response to nivolumab after radical resection?

CXCL10, C-X-C motif chemokine ligand 10; IFN-γ, interferon gamma; TGF-β, transforming growth factor beta.
 Correct

The exploratory biomarker analysis of the CheckMate 274 trial reported estimated treatment-effect hazard ratios (95% CI) of 1.05 (0.64–1.72), 0.71 (0.42–1.20) and 0.28 (0.14–0.54) in patients with low, medium and high IFN-γ gene signatures, respectively.

Abbreviation

IFN-γ, interferon gamma.

Reference

Necchi A, et al. Presented at: ESMO 2022, Paris, France. 9–12 September 2022. Abstr 1737MO.

Post Test Feedback Close
Step 1: Post CE/CME Test Feedback

Please note this feedback form is compulsory to complete your CE/CME evaluation

* = Mandatory Field

Please complete this short online feedback form.
Please indicate how well each statement met your expectations.
Accreditation Close
Accreditation

Please provide your details so that we can send you your certificate, which will be emailed to the address provided. All fields are required.

* = Mandatory Field
Your Accreditation Close
Your Accreditation

Thank you for your submission. Your certificate has been emailed to you.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72